📈 Jumpstart Signal Watchlist — August 07, 2026

🏢 What they do: Mitek Systems, Inc. (MITK) specializes in digital identity verification, authentication, biometrics, mobile image capture, and fraud detection solutions. Its enterprise-grade platform enables secure onboarding, check deposits, transaction protection, and real-time defense against threats like deepfakes and synthetic fraud for banks, fintechs, and other organizations.
- 🎯 Current $18.49 is 8% below 3yr high $20.14 · ⏳ SMA200 $13.34 (current price $18.49 is above) · 💰 Market Cap $834M
- MITK shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 240% (>20%); Revenue growth 18% (>15%); Low LT D/E 0.20 (<1.0); PEG ratio 0.16 (<1.5).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA21 (5.1%)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Mitek Systems (NASDAQ:MITK) Upgraded by Wall Street Zen to "Strong-Buy" Rating — MarketBeat.
🤖 This is positive for MITK because it is a bullish analyst-style rating upgrade, which can support investor demand for the stock. The article also notes the company’s strong quarterly results, reinforcing the favorable tone.
✅ Mitek Systems Q3 Earnings Call Highlights — MarketBeat.
🤖 This article is positive because it says revenue rose 18% year over year to $54 million, adjusted EBITDA margin reached about 38%, and Mitek raised its full-year outlook. It also highlights continued SaaS and fraud/identity momentum.
✅ Mitek Reports Fiscal Third Quarter Revenue of $54.0 Million, Up 18% Year-Over-Year; Raises Full-Year Outlook — Business Wire.
🤖 This is positive because Mitek beat revenue expectations, posted strong profitability metrics, and raised full-year revenue and adjusted EBITDA margin guidance. Markets typically view a beat-and-raise report favorably.
🍭 Bonus (B): 10/10 — Computer Peripheral Equipment (Technology sector)

🏢 What they do: Bioventus Inc. is a global medical device company that develops and commercializes clinically proven, minimally invasive products to relieve pain and address musculoskeletal challenges by enhancing the body's natural healing process .
- 🎯 Current $14.12 is 7% below 3yr high $15.26 · ⏳ SMA200 $8.96 (current price $14.12 is above) · 💰 Market Cap $955M
- BVS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 327% (>20%); ROE 24% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.06 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (10.8%)
- 🔔 Strong above EMA50 (22.6%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 65 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Bioventus Reports Second Quarter Financial Results — GlobeNewswire.
🤖 Bioventus reported Q2 revenue of $153.2 million, up 4% year over year, and adjusted diluted EPS of $0.22, while reaffirming full-year 2026 guidance. The company also announced it is initiating a review of strategic alternatives, which can be supportive for the stock if it leads to a transaction or value-unlocking action.
✅ Bioventus Q2 2026 slides: profits rise, strategic review underway — Investing.com.
🤖 This coverage highlights improved profitability, with adjusted EPS of $0.22 beating expectations, and notes that Bioventus launched a strategic alternatives review. Even though revenue modestly missed consensus, the earnings beat and strategic review are generally favorable for the shares.
⚪️ Bioventus (BVS) Earnings Call Highlights — Yahoo Finance.
🤖 This article summarizes the Q2 results, including EPS in line with estimates and revenue that was only modestly below expectations. The mixed operating performance and reaffirmed guidance make the market impact more balanced than clearly positive or negative.
⚪️ Bioventus (BVS) Q2 Earnings Meet Estimates — Yahoo Finance.
🤖 Bioventus matched EPS expectations at $0.22 per share, but revenue missed consensus by a small margin. That combination of an earnings meet and slight sales miss is typically neutral to mildly mixed for the stock.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: John Wiley & Sons, Inc. (Wiley) is a global research and learning company that publishes over 1,900 peer-reviewed scientific, technical, medical, and scholarly journals along with academic and professional books, encyclopedias, and digital content .
- 🎯 Current $52.33 is 6% below 3yr high $55.72 · ⏳ SMA200 $38.51 (current price $52.33 is above) · 💰 Market Cap $2.7B
- WLY shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (7.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 103% (>20%); ROE 26% (>15%); Low LT D/E 0.81 (<1.0).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 54 in healthy mid-range
- ⚠️ RSI reversing from overbought (54) — BEARISH
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ John Wiley & Sons A stock hits 52-week high at 53.28 USD — Investing.com.
🤖 The article says WLY reached a 52-week high of $53.28, reflecting strong recent price momentum. It also notes the company’s latest quarterly EPS beat expectations and that Wiley declared a quarterly cash dividend, both of which are supportive for sentiment.
⚪️ Sei Investments Co. Boosts Position in John Wiley & Sons, Inc. $WLY — MarketBeat.
🤖 This filing/news item is mainly about an institutional investor increasing its stake in WLY. It also mentions Wiley’s recent EPS beat and mixed analyst views, but the piece is primarily ownership/news-flow rather than a major new fundamental development.
🍭 Bonus (B): 0/10 — Book Publishing

🏢 What they do: American Healthcare REIT, Inc. (NYSE: AHR) is a real estate investment trust that acquires, owns, and operates a diversified portfolio of clinical healthcare properties, focusing primarily on senior housing communities, skilled nursing facilities, and outpatient medical buildings across the United States, the United Kingdom, and the Isle of Man.
- 🎯 Current $56.74 is 2% below 3yr high $57.72 · ⏳ SMA200 $49.65 (current price $56.74 is above) · 💰 Market Cap $11.0B
- AHR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 55/60
- 🏦 Low drawdown (14.1% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 167% (>20%); Revenue growth 27% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ American Healthcare REIT Announces Second Quarter 2026 Results; Increases Full Year 2026 Guidance — Business Wire.
🤖 AHR reported Q2 GAAP EPS of $0.16 and NFFO of $0.54 per share, with same-store NOI up 13.2% year over year. Management also raised full-year 2026 guidance and highlighted improving leverage, which is constructive for the stock.
✅ Earnings call transcript: American Healthcare REIT lifts 2026 outlook in Q2 2026 — Investing.com.
🤖 The transcript shows strong operating momentum, including 28.6% year-over-year growth in normalized FFO and a raised 2026 NFFO outlook. Shares rose in after-hours trading as investors reacted favorably to the results and higher guidance.
✅ American Healthcare REIT (NYSE:AHR) Releases Earnings Results, Beats Estimates By $0.40 EPS — MarketBeat.
🤖 This article emphasizes that AHR beat earnings expectations by a wide margin and updated fiscal 2026 EPS guidance higher. Although revenue missed consensus, the earnings beat and guidance raise are generally positive for sentiment.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: Laureate Education, Inc. (LAUR) owns and operates a network of higher education institutions in Mexico, Peru, and the United States, offering undergraduate and graduate degree programs in business, medicine, health sciences, engineering, and information technology through campus-based, online, and hybrid formats.
- 🎯 Current $38.34 is 5% below 3yr high $40.46 · ⏳ SMA200 $33.76 (current price $38.34 is above) · 💰 Market Cap $5.3B
- LAUR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 51% (>20%); Revenue growth 17% (>15%); ROE 28% (>15%); Low LT D/E 0.14 (<1.0).
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Laureate Education Reports Financial Results For The Second Quarter and Six Months Ended June 30, 2026 — finance.yahoo.com / GlobeNewswire.
🤖 Laureate reported strong Q2 2026 results, with revenue up 17% year over year, net income rising, and adjusted EBITDA increasing. The company also raised full-year 2026 guidance for enrollments, revenue, adjusted EBITDA, and adjusted EPS, which is favorable for the stock.
✅ Laureate Education (LAUR) Q2 Earnings and Revenues Surpass Estimates — finance.yahoo.com / Zacks.
🤖 The article says Laureate beat consensus earnings estimates for the quarter. Earnings and revenue upside versus expectations is typically supportive for the share price.
❌ Laureate Education Shares Fall After JPMorgan Downgrade — finance.yahoo.com.
🤖 JPMorgan downgraded Laureate to Neutral from Overweight, citing valuation concerns. Analyst downgrades can pressure shares because they signal reduced upside expectations.
🍭 Bonus (B): 0/10 — Educational Services

🏢 What they do: A holding company that invests in, acquires, and operates over 300 post-acute healthcare facilities, including skilled nursing, assisted living, memory care, and senior living communities across 17 states.
- 🎯 At/above 3yr high $48.44 (current $48.44) · ⏳ SMA200 $34.13 (current price $48.44 is above) · 💰 Market Cap $7.7B
- PACS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 50/60
- 🏦 Base breakout (range: 8.9%); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 52% (>20%); ROE 24% (>15%); Low LT D/E 0.32 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (6.9%)
- 🔔 Strong above EMA50 (13.6%)
- 📈 RSI at 66 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ PACS lifts 2026 outlook to $5.75B-$5.85B revenue and $640M-$660M adjusted EBITDA amid Eduro acquisition integration — Seeking Alpha.
🤖 The article says PACS raised full-year 2026 revenue and adjusted EBITDA guidance after strong Q2 results, which is typically positive for the stock because it signals improved operating momentum and management confidence.
✅ PACS Group, Inc. Reports Second Quarter 2026 Results — Business Wire.
🤖 PACS reported Q2 revenue of $1.43 billion, net income up 49.8%, and adjusted EPS of $0.63, all of which indicate strong execution and support a positive stock reaction.
✅ PACS Group Inc (PACS) (Q2 2026) Earnings Call Highlights — Yahoo Finance.
🤖 This recap highlights better-than-expected Q2 earnings and revenue plus raised full-year guidance, both of which are favorable signals for investors.
🍭 Bonus (B): 0/10 — Skilled Nursing Care Facilities

🏢 What they do: Sonoco Products Company (SON) is a global manufacturer of packaging for consumer and industrial markets, including metal, fiber, paper, plastic, and flexible packaging products. Its products and services include items such as rigid containers, tubes and cores, closures, protective packaging, and packaging supply-chain solutions for brands in food, beverage, healthcare, and other industries.
- 🎯 Current $58.02 is 6% below 3yr high $61.45 · ⏳ SMA200 $49.46 (current price $58.02 is above) · 💰 Market Cap $5.7B
- SON shows decent technicals supported by positive sentiment.

💎 Quality (Q): 50/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 24% (>20%); ROE 28% (>15%); Low LT D/E 0.39 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Sonoco Aligns Global Consumer Businesses Under Single Leadership Structure — MarketBeat.
🤖 This restructuring news suggests Sonoco is simplifying management of its consumer business, which can improve execution and operating focus. The market appears to have treated it favorably, and it is company-specific news rather than a generic sector update.
✅ Sonoco Products (NYSE:SON) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS — MarketBeat.
🤖 Sonoco reported quarterly EPS of $1.51, ahead of estimates, and revenue of $1.89 billion also slightly topped expectations. The article says the company raised FY 2026 EPS guidance and shares rose after the report, which is positive for the stock.
✅ Sonoco Earnings Beat Estimates on Productivity in Q2, ... — Yahoo Finance.
🤖 This article highlights that Sonoco beat adjusted EPS estimates and notes the stock has outperformed the industry over the past year. Revenue was slightly below year-ago levels, but the earnings beat and operational productivity are supportive for sentiment.
🍭 Bonus (B): 0/10 — Paper & Allied Products